Risk-adapted strategies for the treatment of Hodgkin lymphoma

Bibliography

• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49
   PubMed Web of Science ®Google Scholar
• Re D, Thomas RK, Behringer K, et al. From hodgkin disease to hodgkin lymphoma: biologic insights and therapeutic potential. Blood 2005;105(12):4553-60
   PubMed Web of Science ®Google Scholar
• Surveillance, epidemiology and end results program. Available from: http://seer.cancer.gov/index.html
   Google Scholar
• Townsend W, Linch D. Hodgkin’s lymphoma in adults. Lancet 2012;380:836-47
   PubMed Web of Science ®Google Scholar
• Evens AM, Hutchings M, Diehl V. Treatment of Hodgkin lymphoma: the past, present, and future. Nat Clin Pract Oncol 2008;5:543-56
   PubMedGoogle Scholar
• Koontz MZ, Horning SJ, Balise R, et al. Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. J Clin Oncol 2013;31:592-8
   PubMed Web of Science ®Google Scholar
• DeVita VTJr, Carbone PP. Treatment of hodgkin’s disease. Med Ann Dist Columbia 1967;36(4):232-4
   PubMedGoogle Scholar
• Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004;104:3483-9
   PubMed Web of Science ®Google Scholar
• Hoskin PJ, Lowry L, Horwich A, et al. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin’s Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol 2009;27:5390-6
   PubMed Web of Science ®Google Scholar
• Rueda Dominguez A, Marquez A, Guma J, et al. Treatment of stage I and II Hodgkin’s lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. Ann Oncol 2004;15:1798-804
   PubMed Web of Science ®Google Scholar
• Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-84
   PubMed Web of Science ®Google Scholar
• Eichenauer DA, Thielen I, Haverkamp H, et al. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 2014;123:1658-64
   PubMed Web of Science ®Google Scholar
• Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin’s Lymphoma. N Eng J Med 2012;366:399-408
   PubMed Web of Science ®Google Scholar
• Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006;24:3128-35
   PubMed Web of Science ®Google Scholar
• Straus DJ. Chemotherapy only for localized Hodgkin lymphoma. J Intern Med 2011;270:197-205
   PubMed Web of Science ®Google Scholar
• Hancock SL, Hoppe RT. Long-term complications of treatment and causes of mortality after Hodgkin’s Disease. Semin Radiat Oncol 1996;6:225-42
   PubMedGoogle Scholar
• Deniz K, O’Mahony S, Ross G, et al. Breast cancer in women after treatment for Hodgkin’s disease. Lancet Oncol 2003;4:207-14
   PubMed Web of Science ®Google Scholar
• Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. Jama 2003;290:465-75
   PubMed Web of Science ®Google Scholar
• Galper SL, Yu JB, Mauch PM, et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood 2011;117:412-18
   PubMed Web of Science ®Google Scholar
• De Bruin ML, Dorresteijn LD, van’t Veer MB, et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst 2009;101:928-37
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Bonfante V, Viviani S, et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol 2004;22:2835-41
   PubMed Web of Science ®Google Scholar
• Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010;28:4199-206
   PubMed Web of Science ®Google Scholar
• Laskar S, Gupta T, Vimal S, et al. Consolidation radiation after complete remission in Hodgkin’s disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol 2004;22:62-8
   PubMed Web of Science ®Google Scholar
• Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma: national cancer institute of Canada clinical trials group and the eastern cooperative oncology group. J Clin Oncol 2005;23:4634-42
   PubMed Web of Science ®Google Scholar
• Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin’s disease who achieve a complete response to chemotherapy. J Clin Oncol 2002;20:3765-71
   PubMed Web of Science ®Google Scholar
• Koshy M, Rich SE, Mahmood U, et al. Declining use of radiotherapy in stage I and II Hodgkin’s disease and its effect on survival and secondary malignancies. Int J Radiat Oncol Biol Phys 2012;82:619-25
   PubMed Web of Science ®Google Scholar
• Specht L, Gray RG, Clarke MJ, et al. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin’s disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin’s Disease Collaborative Group. J Clin Oncol 1998;16:830-43
   PubMed Web of Science ®Google Scholar
• Shore T, Nelson N, Weinerman B. A meta-analysis of stages I and II Hodgkin’s disease. Cancer 1990;65:1155-60
   PubMed Web of Science ®Google Scholar
• Herbst C, Rehan FA, Skoetz N, et al. Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma. Cochrane Database Syst Rev 2011;Cd007110
   Google Scholar
• Herbst C, Rehan FA, Brillant C, et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin’s lymphoma: a systematic review. Haematologica 2010;95:494-500
   PubMed Web of Science ®Google Scholar
• Olszewski AJ, Shrestha R, Castillo JJ. Treatment selection and outcomes in early-stage classical hodgkin lymphoma: analysis of the national cancer data base. J Clin Oncol 2015;33:625-33
   PubMed Web of Science ®Google Scholar
• Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 2003;348:2386-95
   PubMed Web of Science ®Google Scholar
• Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009;27:4548-54
   PubMed Web of Science ®Google Scholar
• Sieniawski M, Reineke T, Nogova L, et al. Fertility in male patients with advanced hodgkin lymphoma treated with BEACOPP: a report of the german hodgkin study group (GHSG). Blood 2008;111:71-6
   PubMed Web of Science ®Google Scholar
• van der Kaaij MA, Heutte N, Le Stang N, et al. Gonadal function in males after chemotherapy for early-stage Hodgkin’s lymphoma treated in four subsequent trials by the european organisation for research and treatment of cancer: EORTC lymphoma group and the groupe d’etude des lymphomes de l’adulte. J Clin Oncol 2007;25:2825-32
   PubMed Web of Science ®Google Scholar
• Josting A, Wiedenmann S, Franklin J, et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for hodgkin’s disease: a report from the german hodgkin’s lymphoma study group. J Clin Oncol 2003;21:3440-6
   PubMed Web of Science ®Google Scholar
• Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009;27:805-11
   PubMed Web of Science ®Google Scholar
• Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med 2011;365:203-12
   PubMed Web of Science ®Google Scholar
• Merli F, Luminari S, Mammi C, et al. Long-term follow-up analysis of HD2000 trial comparing ABVD versus BEACOPP versus copp/EBV/CAD in patients with newly diagnosed advanced-stage hodgkin’s lymphoma: a study from the fondazione italiana linfomi. 56th annual meeting and exposition. 6 – 9 December 2014; SA
   Google Scholar
• Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007 25:3746-52
   Google Scholar
• Rigacci L, Puccini B, Zinzani PL, et al. The prognostic value of positron emission tomography performed after two courses (interim-pet) of standard therapy on treatment outcome in early stage hodgkin lymphoma. A multicentric study by the fondazione italiana linfomi (FIL). Am J Hematol 2015;90(6):499-503
   PubMed Web of Science ®Google Scholar
• Gallamini A, Barrington SF, Biggi A, et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica 2014;99:1107-13
   PubMed Web of Science ®Google Scholar
• Oki Y, Chuang H, Chasen B, et al. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol 2014;165:112-16
   PubMed Web of Science ®Google Scholar
• Dann EJ, Bar-Shalom R, Tamir A, et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007;109:905-9
   PubMed Web of Science ®Google Scholar
• Avigdor A, Bulvik S, Levi I, et al. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin’s lymphoma. Ann Oncol 2010;21:126-32
   PubMed Web of Science ®Google Scholar
• Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-6
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32:3059-68
   PubMed Web of Science ®Google Scholar
• Network NCC: Hodgkin Lymphoma (Version 2.2014)
   Google Scholar
• Cosset JM, Henry-Amar M, Meerwaldt JH, et al. The EORTC trials for limited stage Hodgkin’s disease. The EORTC Lymphoma Cooperative Group. Eur J Cancer 1992;28a:1847-50
   PubMed Web of Science ®Google Scholar
• Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 363:640-52.2010
   PubMed Web of Science ®Google Scholar
• Tubiana M, Henry-Amar M, Carde P, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin’s disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood 1989;73:47-56
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. international prognostic factors project on advanced hodgkin’s disease. N Engl J Med 1998;339:1506-14
   PubMed Web of Science ®Google Scholar
• Moccia AA, Donaldson J, Chhanabhai M, et al. International Prognostic Score in advanced-stage Hodgkin’s lymphoma: altered utility in the modern era. J Clin Oncol 2012;30:3383-8
   PubMed Web of Science ®Google Scholar
• Brusamolino E, Lazzarino M, Orlandi E, et al. Early-stage Hodgkin’s disease: long-term results with radiotherapy alone or combined radiotherapy and chemotherapy. Ann Oncol 1994;5(Suppl 2):101-6
   PubMedGoogle Scholar
• Canellos GP, Abramson JS, Fisher DC, et al. Treatment of favorable, limited-stage Hodgkin’s lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol 2010;28:1611-15
   PubMed Web of Science ®Google Scholar
• Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 2003;21:3601-8
   PubMed Web of Science ®Google Scholar
• von Tresckow B, Plutschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 2012;30:907-13
   PubMed Web of Science ®Google Scholar
• Advani R, Hong F, Fisher RI, et al. Randomized Phase III Trial Comparing ABVD + Radiotherapy and the Stanford V Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the US Intergroup Trial E2496. ASH Annual Meeting Abstracts, Orlando, FL 2010. p. 116-416
   Google Scholar
• Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006;107:52-9
   PubMed Web of Science ®Google Scholar
• Barrington SF, Qian W, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2010;37:1824-33
   PubMed Web of Science ®Google Scholar
• Radford J, Barrington S, Counsell N, et al. Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA hodgkin lymphoma and a ’negative’ PET scan after 3 cycles ABVD. results of the UK NCRI RAPID trial. ASH Annual Meeting Abstracts, Atlanta, GA 2012. p. 120-547
   Google Scholar
• Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage hodgkin’s lymphoma. N Eng J Med 2015;372:1598-607
   PubMed Web of Science ®Google Scholar
• Andre MP, Reman O, Federico M, et al. Interim Analysis of the Randomized Eortc/Lysa/Fil Intergroup H10 Trial On Early PET-Scan Driven Treatment Adaptation in Stage I/II Hodgkin Lymphoma. ASH Annual Meeting Abstracts, Atlanta, GA. 2012. p. 120-549
   Google Scholar
• Raemaekers JM, Andre MP, Federico M, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 2014;32:1188-94
   PubMed Web of Science ®Google Scholar
• Picardi M, De Renzo A, Pane F, et al. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin’s lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma 2007;48:1721-7
   PubMed Web of Science ®Google Scholar
• HD16 for early stage hodgkin lymphoma. https://clinicaltrials.gov/ct2/show/NCT00736320
   Google Scholar
• HD17 for intermediate stage hodgkin lymphoma. http://clinicaltrials.gov/show/NCT01356680 [Last accessed 15 May 2014]
   Google Scholar
• Response-Based therapy assessed By PET scan in treating patients with bulky stage I and stage II classical hodgkin lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01118026 [Last accessed 24 october 2014]
   Google Scholar
• Chemotherapy based on positron emission tomography scan in treating patients with stage I or stage II hodgkin lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01132807 [Last accessed 25 october 2014]
   Google Scholar
• Eichenauer DA, Engert A, Andre M, et al. Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25(Suppl 3):iii70-5
   PubMed Web of Science ®Google Scholar
• Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol 2003;21:607-14
   PubMed Web of Science ®Google Scholar
• Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 2013;31:684-91
   PubMed Web of Science ®Google Scholar
• Loeffler M, Brosteanu O, Hasenclever D, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin’s disease. International Database on Hodgkin’s Disease Overview Study Group. J Clin Oncol 1998;16:818-29
   PubMed Web of Science ®Google Scholar
• Aleman BM, Raemaekers JM, Tirelli U, et al. Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med 2003;348:2396-406
   PubMed Web of Science ®Google Scholar
• Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012;379:1791-9
   PubMed Web of Science ®Google Scholar
• Gallamini A, Patti C, Viviani S, et al. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol 2011;152:551-60
   PubMed Web of Science ®Google Scholar
• Johnson P, Massimo F, Fossa A, et al. Response rates and toxicity of response-adapted therapy in advanced Hodgkin lymphoma: initial results from the international RATHL study. Hamatologica 2013;98(suppl 2):02; Abstract T003
   PubMedGoogle Scholar
• Johnson PF, Fossa M, O’Doherty A, et al. Response-adapted therapy based on interim FDG-PET scans in advanced Hodgkin Lymphoma: first analysis of the safety of de-escalation and efficacy of escalation in the international RATHL study (CRUK/07/033). Hematological Oncology 2015;33(supp 1): Abstract 008, 2014
   PubMedGoogle Scholar
• Press OW LM, Rimsza LM, et al. A Phase II Trial of response-adapted therapy of stages II-IV hodgkin lymphoma using early interim FDG-PET imaging: US intergroup S0816. Hematological Oncology 2013;31(S1; Abstract 124
   Google Scholar
• Dann EJ BO, Bar-Shalom R, et al. Tailored therapy in Hodgkin lymphoma, based on predefined risk factors and early interim PET/CT, Israeli H2 protocol: preliminary report on 317 patients. Haematologica 2013;98(Suppl 2):37
   Google Scholar
• Zinzani PL BM, Rossi G, et al. Early salvage with high-dose chemotherapy and stem cell transplantation in advanced stage Hodgkin’s lymphoma patients with positive positron emission tomography after two courses of chemotherapy: preliminary results of the IIL-HD0801 study. Haematologica 2013;98(Suppl 2):6
   Google Scholar
• Gallamini A, Rossi A, Patti C, et al. Early treatment intensification in advanced-stage high-risk hodgkin lymphoma (HL) patients, with a positive FDG-PET scan after two ABVD courses - first interim analysis of the GITIL/FIL HD0607 clinical trial. ASH Annual meeting abstracts, Atlanta, GA 2012. p. 120-550
   Google Scholar
• Gallamini AR, Patti A, Picardi C, et al. Early treatment intensification in advanced-stage high-risk Hodgkin Lymphoma (HL) patients, with a positive fdg-pet scan after two abvd courses – Second interim analysis of the GITIL/FIL HD0607 clinical trial. Haematologica 2013;98(suppl 2): Abstract P006
   Google Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 2012;30:2183-9
   PubMed Web of Science ®Google Scholar
• Sasse S, Rothe A, Goergen H, et al. Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma. Leuk Lymphoma 2013;54:2144-8
   PubMed Web of Science ®Google Scholar
• Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol 2013;14:1348-56
   PubMed Web of Science ®Google Scholar
• Brentuximab vedotin plus AVD in limited-stage hodgkin lymphoma. Available from: www.clinicaltrials.gov/ct2/show/NCT01534078 [Last accessed 29 October 2014]
   Google Scholar
• Phase 3 frontline therapy trial in patients with advanced classical hodgkin lymphoma. Available from: www.clinicaltrials.gov/ct2/show/NCT01712490 [Last accessed 13 August 2014]
   Google Scholar
• Kasamon YL, Jacene HA, Gocke CD, et al. Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood 2012;119:4129-32
   PubMed Web of Science ®Google Scholar
• A trial of pembrolizumab (MK-3475) in participants with blood cancers (MK-3475-013)(KEYNOTE-013). Available from: http://clinicaltrials.gov/show/NCT01953692. [ Last accessed 11 September 2014]
   Google Scholar
• Johnston PB, Inwards DJ, Colgan JP, et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010;85:320-4
   PubMed Web of Science ®Google Scholar
• Kirschbaum MH, Goldman BH, Zain JM, et al. A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. Leuk Lymphoma 2012;53:259-62
   PubMed Web of Science ®Google Scholar
• Younes A, Oki Y, Bociek RG, et al. Mocetinostat for relapsed classical Hodgkin’s lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2011;12:1222-8
   PubMed Web of Science ®Google Scholar
• Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol 2012;30:2197-203
   PubMed Web of Science ®Google Scholar
• Jona A, Khaskhely N, Buglio D, et al. The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. Exp Hematol 2011;39:1007-17.e1
   PubMed Web of Science ®Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory hodgkin’s lymphoma. N Eng J Med 2015;372:311-19
   PubMed Web of Science ®Google Scholar
• Positron emission tomography (PET)-adapted chemotherapy in advanced hodgkin lymphoma (HL) (HD0607). Available from: https://clinicaltrials.gov/ct2/show/NCT00795613 [Last accessed 3 December 2015]
   Google Scholar
• S0816 Fludeoxyglucose F 18-PET/CT imaging and combination chemotherapy with or without additional chemotherapy and G-CSF in treating patients with stage III or stage IV hodgkin lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT00822120 [Last accessed 2 December 2015]
   Google Scholar